Ligand Pharmaceuticals Appoints New Chief Medical Officer
Ticker: LGNZZ · Form: 8-K · Filed: Aug 2, 2024 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Aug 2, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $47,808.33, $23,904.17, $7,171.25 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: LGND
TL;DR
Ligand Pharma names Dr. Adlakha as new CMO, replacing Dr. McLellan.
AI Summary
Ligand Pharmaceuticals Inc. announced on August 2, 2024, the appointment of Dr. Jason L. Adlakha as its new Chief Medical Officer. Dr. Adlakha previously served as Senior Vice President, Medical Affairs at Ligand. The company also reported the departure of Dr. John P. McLellan from his role as Chief Medical Officer.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could influence the company's drug development strategy and clinical trial execution.
Risk Assessment
Risk Level: low — This filing primarily concerns a change in executive leadership, which is a routine corporate event and does not immediately indicate significant financial or operational risks.
Key Players & Entities
- Ligand Pharmaceuticals Inc. (company) — The reporting company.
- Dr. Jason L. Adlakha (person) — Newly appointed Chief Medical Officer.
- Dr. John P. McLellan (person) — Departing Chief Medical Officer.
- August 2, 2024 (date) — Date of the reported event.
FAQ
Who has been appointed as the new Chief Medical Officer of Ligand Pharmaceuticals?
Dr. Jason L. Adlakha has been appointed as the new Chief Medical Officer of Ligand Pharmaceuticals.
What was Dr. Adlakha's previous role at Ligand Pharmaceuticals?
Dr. Adlakha previously served as Senior Vice President, Medical Affairs at Ligand Pharmaceuticals.
Who has departed from the role of Chief Medical Officer?
Dr. John P. McLellan has departed from the role of Chief Medical Officer.
On what date was this change in executive leadership reported?
This change in executive leadership was reported on August 2, 2024.
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report the departure of a director or certain officers and the appointment of certain officers.
Filing Stats: 915 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-08-02 17:15:58
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market
- $47,808.33 — period, Mr. Korenberg will be paid (a) $47,808.33 per month until October 31, 2024, (b) $
- $23,904.17 — 3 per month until October 31, 2024, (b) $23,904.17 per month from October 31, 2024 until t
- $7,171.25 — oyed other than by the Company, and (c) $7,171.25 per month from and after the later of O
Filing Documents
- lgnd-20240802.htm (8-K) — 26KB
- 0000886163-24-000064.txt ( ) — 149KB
- lgnd-20240802.xsd (EX-101.SCH) — 2KB
- lgnd-20240802_lab.xml (EX-101.LAB) — 22KB
- lgnd-20240802_pre.xml (EX-101.PRE) — 13KB
- lgnd-20240802_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: August 2, 2024 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary